Search Results 1321-1330 of 18716 for Relapse
... relapse prevention. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...
... relapse and reduction in corticosteroid requirement. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...
... relapsed NSCLC. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma. Rochester, Minn ...
Patients at high risk of relapse are eligible for InPACT-pelvis, where they ... Also, to improve disease control by decreasing the number of spinal relapses ...
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia ...
Participants with non-squamous NSCLC: has relapsed from or is refractory to standard treatment or for which no standard treatment is available. Participants ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.